MICHAEL R MIGDEN to Treatment Outcome
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Treatment Outcome.
Connection Strength
0.411
-
Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective. Future Oncol. 2021 Dec; 17(35):4971-4982.
Score: 0.044
-
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021 08; 9(8).
Score: 0.043
-
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncol. 2020 Feb; 16(4):11-19.
Score: 0.039
-
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 02; 21(2):294-305.
Score: 0.039
-
Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):947-951.
Score: 0.038
-
Severe pretibial myxedema refractory to systemic immunosuppressants. Cutis. 2019 Sep; 104(3):E1-E3.
Score: 0.038
-
Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. Future Oncol. 2019 Sep; 15(27):3171-3184.
Score: 0.038
-
Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol. 2018 Mar; 14(6):515-525.
Score: 0.034
-
Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncol. 2016 Sep; 12(18):2095-105.
Score: 0.030
-
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun; 16(6):716-28.
Score: 0.028
-
Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42?months. J Am Acad Dermatol. 2021 Apr; 84(4):1162-1164.
Score: 0.010
-
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar; 32(3):372-381.
Score: 0.008
-
Safety and efficacy of vismodegib in patients aged =65 years with advanced basal cell carcinoma. Oncotarget. 2016 11 15; 7(46):76118-76124.
Score: 0.008
-
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72(6):1021-6.e8.
Score: 0.007
-
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 07; 366(23):2171-9.
Score: 0.006